After a distinguished career navigating Asia’s capital markets, Danny Chen successfully pivoted to the deep-tech sector to drive healthcare innovation. As the Chief Operating Officer at Illuminatio Medical Technology, a CUHK spin-off, he leads the commercialization of cutting-edge MRI technologies. This transition was accelerated by his co-founding of New Atlas Capital during his CUHK MBA, an investment bank aiming to empower early-stage ventures through business consulting, venture building and fundraising. Danny’s deep-tech leadership is built on a formidable financial foundation. His previous roles span from analyzing healthcare at a Shenzhen fund house to leading China auto equity research at GCS-CIMB Securities, and orchestrating debt restructuring at a HK-listed company. Holding a bachelor’s degree from HKU, Danny leverages his extensive background in securities analysis and corporate finance to accelerate the growth of transformative deep-tech enterprises.

From Outsider to Insider: What I Learned from Deep-Tech Transfer in Hong Kong I left HKU for securities analysis and spent years pricing other people's companies from the outside. Healthcare at a Shenzhen fund house. China auto equity research at GCS-CIMB Securities. Debt restructuring at a Hong Kong-listed company. Then I crossed the table. Today I am Chief Operating Officer at Illuminatio Medical Technology, a CUHK spin-off commercializing MRI technology, and I co-founded New Atlas Capital during my CUHK MBA to build and fund early-stage ventures. The move taught me three things I wish someone had told the researchers I now work with. First, the idea I will spend most time on. Technology sets a startup's ceiling. Venture building sets its floor. A breakthrough in the lab defines how high the company could go; the team, the structure, the operating discipline and the sequence of decisions decide how low it can fall. Most deep-tech companies do not die of a ceiling problem. They die on the floor. Raising the floor is unglamorous, learnable work, worth more than another point of technical performance. Second, understand the nature of your technology before you pick a strategy. Regulatory path, capital intensity, sales cycle, who signs the cheque: these are properties of the technology, not of a playbook. A medical imaging system and a software platform cannot share a route to market. Third, find the right investors rather than the largest cheque. Investor fit is a strategic choice made early, not a fundraising outcome discovered late. I will close on Hong Kong, where the response to a real commercialization gap has been serious. RAISe+ has committed over HK$3 billion across 73 projects. TSSSU+ matches private capital dollar for dollar. CUHK's Deep-Tech Lab and HKSTP are turning papers into companies, with the Greater Bay Area next door. If you are sitting on technology you do not know how to commercialize, you will leave with somewhere to start.